PET imaging approaches for inflammatory lung diseases: Current concepts and future directions.
Inflammatory lung disease is one of the most common clinical scenarios, and yet, it is often poorly understood. Inflammatory lung disorders, such as chronic obstructive pulmonary diseases, which are causing significant mortality and morbidity, have limited therapeutic options. Recently, new treatments have become available for pulmonary fibrosis. This review article will describe the new insights that are starting to be gained from positron emission tomography (PET) methods, by targeting molecular processes using dedicated radiotracers. Ultimately, this should aid in deriving better pathophysiological classification of these disorders, which will ultimately result in better evaluation of novel therapies.
Divisions of Radiological Sciences and Nuclear Medicine, Mallinckrodt Institute of Radiology, Campus Box 8225, 510S, Kingshighway Blvd, St. Louis, MO, USA. Electronic address: chend@wustl.edu.
Delphine L
DL
Chen
Department of Radiology, UW-Madison School of Medicine and Public Heath, Madison, WI, USA.
Mark L
ML
Schiebler
Department of Radiology, Seoul National University, Seoul, Korea.
Jin Mo
JM
Goo
Clinical Research Imaging Centre, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Edwin J R
EJR
van Beek
D001249:Asthma / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D010455:Peptides; D011014:Pneumonia / Q000000981:diagnostic imaging; D011092:Polyethylene Glycols; D049268:Positron-Emission Tomography / Q000379:methods*; D029424:Pulmonary Disease, Chronic Obstructive / Q000000981:diagnostic imaging*; D011658:Pulmonary Fibrosis / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals
C530281:AH 111585; D010455:Peptides; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D011092:Polyethylene Glycols
(18)F-NOS; (18)Fluoro-fluciclatide; (18)Fluorodeoxyglucose; Asthma; COPD; Positron emission tomography; Pulmonary fibrosis